Topics

Ankylosing Spondylitis

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Etanercept for Spondyloarthritis: Impact on Disease Progression

The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Sign Up for Free e-newsletters